Materials & Resources » Chemicals | Hubei Biocause Pharmaceutical Co. Ltd.

Hubei Biocause Pharmaceutical Co. Ltd. A | Income Statement

Fiscal year is January-December. All values CNY Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
966
805
539
16,197
53,098
30,111
Unusual Expense
18
47
101
45
1
1,058
Pretax Income
130
123
194
2,636
2,471
2,488
Equity in Affiliates
1
14
529
796
254
149
Consolidated Net Income
100
84
251
3,109
2,678
2,377
Net Income
101
84
247
1,779
1,326
1,327
Net Income After Extraordinaries
101
84
247
1,779
1,326
1,327
Net Income Available to Common
101
84
247
1,779
1,326
1,327
EPS (Basic)
0.07
0.06
0.18
0.44
0.30
0.27
Basic Shares Outstanding
1,354
1,354
1,354
4,043
4,941
4,941
EPS (Diluted)
0.07
0.06
0.18
0.44
0.27
0.27
Diluted Shares Outstanding
1,354
1,354
1,354
4,043
4,941
4,941
Minority Interest Expense
-
1
3
1,330
1,352
1,051
Income Taxes
28
25
84
324
46
259
Non-Operating Income (Expense)
11
337
19
8
1
185
Losses, Claims & Reserves
-
-
-
10,000
45,284
21,300
Selling, General & Admin. Expenses & Other
45
50
50
3,440
5,285
5,331
Operating Income Before Interest Expense
92
135
88
2,757
2,529
3,480
Interest Expense, Net of Interest Capitalized
30
32
25
84
60
118
Operating Income After Interest Expense
123
167
113
2,673
2,469
3,361
Reserves Increase (Decrease)
2
3
4
15
7
16

About Hubei Biocause Pharmaceutical Co.

View Profile
Address
No. 132 Yangwan Road
Jingmen Hubei 448000
China
Employees -
Website http://www.biocause.com
Updated 07/08/2019
Hubei Biocause Pharmaceutical Co., Ltd. engages in the research, development, manufacture and sale of chemical products and medicinal raw materials. Its products include homatropine hydrobromide, thiotriazoline, lercanidipine hydrochloride, barnidipine hydrochloride, mitoxantrone hydrochloride, hyoscyamine sulfate, balsalazide sodium, oxaprozin, homatropine methyl bromide, flumazenil, milrinone, granisetron hydrochloride and others. The company was founded on November 18, 1993 and is headquartered in Jingmen, China.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.